Singapore’s Health Sciences Authority (HSA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) have signed a Memorandum of Cooperation (MOC) to deepen collaboration through regulatory reliance mechanisms for health products, strengthening ties between two advanced regulatory systems. The agreement, signed on 20 April 2026 in Tokyo, formalizes a framework for greater alignment across the product lifecycle, from clinical trials review and marketing authorization to manufacturing and post‑market oversight; for medicines, cell‑ and gene‑therapy products, and medical devices.
The MOC builds on years of prior cooperation under the Japan–Singapore Economic Partnership Agreement (JSEPA) and earlier information‑exchange arrangements, and now explicitly embeds reliance‑based pathways that allow each authority to leverage the other’s assessments where appropriate. This is expected to reduce duplication, shorten review timelines, and support faster, more predictable access to innovative health products for patients while maintaining high standards of safety and efficacy. For industry, the arrangement provides a clearer regulatory environment when planning cross‑border submissions and lifecycle‑management strategies between Singapore and Japan.
From a compliance perspective, the agreement signals a continued push towards harmonized, reliance‑based review models, similar to HSA’s existing reliance initiatives with other reference agencies. Regulated entities should expect increased expectations for robust data, consistent quality systems, and transparent post‑market reporting, as both agencies seek to balance efficiency with robust oversight under these new collaborative structures.
Kindly refer to the following press release from HSA: